PRF110

Phase 2UNKNOWN
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post Operative Pain

Conditions

Post Operative Pain

Trial Timeline

Aug 1, 2016 → Jun 1, 2017

About PRF110

PRF110 is a phase 2 stage product being developed by PainReform for Post Operative Pain. The current trial status is unknown. This product is registered under clinical trial identifier NCT02784327. Target conditions include Post Operative Pain.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02784327Phase 2UNKNOWN

Competing Products

20 competing products in Post Operative Pain

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
44
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
28
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
Placebo + DS-5565Daiichi SankyoPre-clinical
23
YM177 + etodolac + PlaceboAstellas PharmaPhase 3
77
QUTENZAAstellas PharmaApproved
85
QutenzaAstellas PharmaPre-clinical
23
CelecoxibAstellas PharmaPre-clinical
23
ASP8477 + PlaceboAstellas PharmaPhase 2
52
Naldemedine + PlaceboShionogiPhase 2
52